fda compounding semaglutide warning letters news Troubling Findings in Study of GLP-1 Compounders US FDA sends 25 letters

Leaving medication in your car : Heat in parked cars can exceed 100F quickly even with tinted windows

Food and Drug Administration (FDA) for diabetes treatment and not obesity

Beyond the Scale Scale weight tells only part of the story

At week 52, both dulaglutide doses produced superior glycaemic control to sitagliptin, with mean HbA 1c reductions of 1.1% and 0.87% versus 0.39%, respectively (p.0.001 for both comparisons)

Rapid weight loss: 20-24% weight loss in 48 weeks

Today, studies estimate that over 80 percent of the personalized compounded GLP-1 drugs now being marketed include added ingredients such as B vitamins (B6, B12, B3)